Citations

Showing 10 of 108083 citations.

Posttransplant cyclophosphamide as a platform for immunotherapy after allogeneic stem cell transplantation for multiple myeloma
Kuns, Rachel D. , Ensbey, Kathleen S., Samson, Luke, Chesi, Marta, Vučković, Slavica , Minnie, Simone A. , Chesi, Marta , Gartlan, Kate H. , Smyth, Mark J. , Hill, Geoffrey R.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 87.30-87.30

10.4049/jimmunol.204.supp.87.30 Get It

Abstract Allogeneic stem cell transplantation (alloSCT) is a highly effective, curative therapy for leukemia yet does not provide a survival benefit above autologous SCT in patients with multiple myeloma (MM). To explore this, we developed preclinical models of SCT using C57Bl/6 recipient mice and either C57Bl/6 (ASCT) or C3H.SW (alloSCT) donor grafts. Importantly, these models recapitulated the clinical setting whereby alloSCT provided superior outcomes, compared to ASCT, in recipients bearing MLL-AF9-driven acute myeloid leukemia (AML) but not in those bearing Vk*MYC-MM. Interestingly, we found that MM-specific, T cell-mediated immunity was generated after ASCT, which failed due to MM-induced T cell exhaustion. MM relapse after ASCT could be prevented by TIGIT or PD-1 targeted immune checkpoint inhibition or via depletion of suppressive CSF1-R+ myeloid cells. Conversely, after alloSCT, T cell exhaustion was driven principally by alloantigen and CD8 T cells expressed high levels of PD-1, TIGIT and TIM-3. Furthermore, Vk*MYC myeloma exploited this alloantigen-driven T cell exhaustion via expression of high levels of PD-L1 and CD155 (the cognate ligands for PD-1 and TIGIT), which were expressed minimally on MLL-AF9 AML. To exploit alloSCT in MM, we used post-transplant cyclophosphamide (PT-Cy) to delete high affinity alloreactive T cells that generate the exhausted donor T cell pool. Subsequent administration of CD137 agonists enhanced T cell activation and cytolytic activity within bone marrow, without exacerbating GVHD. Thus, PT-Cy provides a platform for optimizing immunotherapy after alloSCT.
Development of a platform for screening patient-derived CD8+ T cell responses against autoantigens
Johnson, Renee K., Clarkson, Ben D.S., Howe, Charles L.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 64.32-64.32

10.4049/jimmunol.204.supp.64.32 Get It

Abstract Cytotoxic CD8+ T cells outnumber CD4+ T cells within multiple sclerosis (MS) lesions, yet the pathogenic role for these cells and the relevant target antigen(s) involved in neuropathology remain unknown. We predict that a subset of lesion-infiltrating CD8+ T cells are specific for neuronal antigens and contribute to axon or neuron injury, thereby driving disease progression and accumulation of disability. To test this, we are developing protocols to measure MS patient-derived T cell reactivity against neuronal and control antigens. Peripheral blood mononuclear cells (PBMCs) isolated from whole blood were incubated with GM-CSF and IL-4 to selectively expand dendritic cells (DCs) or with IL-7 to promote survival and maintenance of T cells. After resting, patient T cells were combined 1:1 with autologous DCs in the presence of vaccine antigens or peptides derived from common pathogens. We tested responses against a pool of cytomegalovirus, Epstein Barr virus, and influenza peptides (CEF) and against mumps viral protein extract. We also tested responses in T cells derived from patients with autoimmune neurological disorders following incubation with autologous DCs and disease-specific proteins. Activation profiles were assessed using CD69, CD44, and LFA-1 by conventional flow cytometry. Cellular responses were also assessed using mass cytometry (cytometry by time of flight; CyTOF). Our next steps include testing MS patient-derived T cell responses against neuronal and axonal protein libraries, with the goal of identifying potential autoantigens that underlie disease progression.
Affinity threshold conversion: the progressive differentiation checkpoint at which the TCRα/CD3δ signaling axis controls thymic positive selection
Canfield, Jenna M. , Neier, Steven C. , Wilton, Katelynn M. , Stiles, Robert J. , Davis, Tessa R. , Pages, Diana Gil, Ferrer, Alejandro , Schrum, Adam G.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 61.15-61.15

10.4049/jimmunol.204.supp.61.15 Get It

Abstract Upon positive selection of conventional αβ T cells, CD4+ CD8+ double-positive (DP) cells transition to single-positive (SP) and reduce their responsiveness to weak peptide/MHC ligands (affinity threshold conversion, ATC). We report that ATC actually begins prior to the completion of positive selection in the DP stage, and this checkpoint is where the TCRα/CD3δ signaling axis controls positive selection. We dissected ATC in the OT1 TCR transgenic system in conjunction with several different genes whose null mutations block thymic development at DP stage: β2m, CD3δ, and/or TCRα-Connecting Peptide Motif (αCPM). In the absence of MHC class I (β2m0), CD3δ or αCPM mutants were blocked at pre-selection DP stage and displayed immature, high-sensitivity to weak TCR ligands. In contrast, when MHC class I was present (β2m+), CD3δ or αCPM mutants were blocked at DP stage but underwent partial ATC; they began positive selection but did not complete it. Upon exogenous TCR engagement of partial-ATC thymocytes, the proximal signaling protein interaction network showed overall weakened activity, notably decreasing SOS1 participation linked to the downstream Ras/Raf/ERK selection pathway. Provision of high affinity peptide/MHC in FTOC rescued completion of positive selection for partial-ATC mutant thymocytes. Finally, comparing nontransgenic, polyclonal B6 vs. CD3δ0 DP thymocytes, although most cells showed equal maturation state, a subset of cells in B6 progressed in maturation relative to CD3δ0. We propose the existence of an intermediate checkpoint inside DP stage, in which ATC already begins to reduce responsiveness to selection ligands, yet further TCR signaling is required to complete positive selection.
Glutamine metabolism is required for alveolar macrophage proliferation
Wang, Min , Sun, Jie , Zhu, Bibo , Sun, Jie

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 248.18-248.18

10.4049/jimmunol.204.supp.248.18 Get It

Abstract Alveolar macrophages (AMs) are the most abundant immune cells in the lung during homeostasis. AMs are critical for normal lung development, surfactant metabolism and host defense against various respiratory pathogens. Despite being terminally differentiated cells, AMs are able to proliferate and self-renew to maintain their compartment without the input of the hematopoietic system in the adulthood during homeostasis. However, the molecular and metabolic mechanisms modulating AM proliferative responses are still incompletely understood. Here we have investigated the metabolic regulation of AM proliferation and self-renewal. We found that mitochondrial metabolism is critical for AM proliferation in vitro and in vivo. Interestingly, inhibition of glucose uptake or fatty acid oxidation did not significantly impact AM proliferation. Rather, inhibition of the glutamine metabolic process abolished AM proliferation in vitro and in vivo following their partial depletion during influenza infection. We further demonstrated that glutamine metabolism was required for AM mitochondrial respiration. Our data indicate that glutamine is a critical substrate fueling mitochondrial metabolism required for AM proliferation. Our study is expected to shed light on the metabolic regulation of AM maintenance and repopulation during homeostasis and following acute respiratory viral infection.
Regulation of the immune response by ST8Sia6
Crotts, Sydney B. , Wang, Zheng , Shapiro, Michael J. , Rajcula, Matthew, McCue, Shaylene , Sun, Jie , Friedman, David J. , Shapiro, Michael J, Sun, Jie , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 228.18-228.18

10.4049/jimmunol.204.supp.228.18 Get It

Abstract Sialic acids are the terminal modification on glycoproteins and glycolipids. The sialic acid transferase ST8Sia6 generates a2,8-linked disialic acids on O-linked glycoproteins, which bind to the inhibitory receptor Siglec-E on innate immune cells and suppress immune activation. Recently, our lab has shown that ST8Sia6 expression on tumor cells inhibits the immune response through Siglec-E, leading to increased tumor growth and decreased survival. Therefore, the products of ST8Sia6 can modulate the immune response to tumors. Our lab has generated ST8Sia6 knockout (KO) mice, and we seek to understand the role of ST8Sia6 in regulating the immune response to pathogens. We find that ST8Sia6 KO mice, when challenged with influenza virus, clear the infection significantly faster than wildtype controls, suggesting that absence of ST8Sia6 reduces inhibition of the innate compartment, thereby increasing immune recruitment to infection. This data suggests an important role for interactions between Siglec-E and ST8Sia6-generated disialic acids in immune regulation and recruitment to infection sites.
Runx1 is a key regulator of T cell anergy
Wilfahrt, Drew Nicholas, Hsu, Fan Chi, McCue, Shaylene , Rajcula, Matthew, Hsu, Fan‐Chi , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 228.9-228.9

10.4049/jimmunol.204.supp.228.9 Get It

Abstract T cell anergy is a state of cellular hyporesponsiveness that prevents the propagation of an immune response to self. Consequently, the development and maintenance of the anergy program in T cells is tightly controlled. We found in wild type (WT) mice that anergic T cells, defined by co-expression of the cell surface markers CD73 and FR4, express lower expression of the transcription factor Runx1. To test if Runx1 acts as a negative regulator of the anergy program, we utilized a 1:1 mixed bone marrow chimera (BMC) system with ER-Cre Runx1 cKO and WT B6.SJL bone marrow to delete Runx1 in mature CD4+ T cells. Upon tamoxifen treatment and deletion of Runx1, ER-Cre Runx1 cKO CD4+ T cells develop a CD73+FR4+ anergic phenotype. This effect is cell-intrinsic since WT T cells from the same bone marrow chimera do not exhibit the anergic phenotype. Functionally, ER-Cre Runx1 cKO T cells fail to proliferate and produce less IL-2 after TCR/CD28 stimulation, consistent with anergy. Interestingly, WT B6.SJL T cells from the ER-Cre Runx1 cKO:B6.SJL BMC mice fail to proliferate in response to TCR/CD28 stimulation, suggesting Runx1 additionally regulates a cell-extrinsic suppressive mechanism. Using depletion experiments, we found this extrinsic suppression requires FR4+ anergic T cells, but not CD25+ Tregs. Interestingly, the loss of Runx1 leads to the generation of CD73+FR4+ anergy in OT-II T cells, which do not engage their TCR. Thus, the loss of Runx1 drives anergy in the absence of TCR signaling. We conducted RNA-sequencing on ER-Cre Runx1 cKO and WT anergic T cells, and have identified several genes regulated by Runx1 that could play a role in anergy. Further analysis will serve to define the molecular mechanisms Runx1 employs to regulate T cell anergy.
Super-induction of immunosuppressive glioblastoma extracellular vesicles by IFN-g through PD-L1 and IDO1
Garcia, Luz Milbeth Cumba, Jung, Mi-Yeon, Brown, Desmond , Himes, Benjamin , Parney, Ian F.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 229.13-229.13

10.4049/jimmunol.204.supp.229.13 Get It

Abstract Glioblastoma is the most common and aggressive primary brain tumor. Median survival is 15 months despite surgery, radiation, and chemotherapy. Immunotherapy is promising but glioblastoma-mediated immunosuppression remains a barrier. Recently, extracellular vesicles (EVs) have been implicated in glioblastoma-mediated immunosuppression through expression of the immune checkpoint molecules PD-L1 and IDO1 which have been implicated in T cell function suppression and decreased proliferation in some cancers. Our data demonstrate that PD-L1 and IDO1 expression are increased in most nucleated cells following IFN-γ exposure. IFN-γ exposure did not alter EV production or expression of common EV markers but increased PD-L1 and IDO1 expression in EVs from differentiated but not stem-like GBM cells. Differentiated glioblastoma cell derived EVs induced myeloid-derived suppressor cell and non-classical monocyte differentiation from normal monocytes. This was increased following IFN-γ exposure and was dependent upon both PD-L1 and IDO1 expression but not stem-like GBM cell. Monocytes exposed to differentiated but not stem-like GBM cell EVs inhibited T cell proliferation in a similar manner (increased with IFN-γ exposure, decreased with PD-L1 or IDO1 knockdown). Thus, IFN-γ exposure results in super-induction of immunosuppressive EVs from differentiated but not stem-like GBM cells that increase MDSC and NCM differentiation in normal monocytes and increase their ability to inhibit T cell proliferation. These effects are dependent upon PD-L1 and IDO1 up-regulation induced by IFN-γ. This may be an important mechanism GBMs utilize to suppress anti-tumor T cell responses that are typically accompanied by increased IFN-γ expression.
Baby’s First Macrophage: characterizing Hofbauer Cell phenotype through gestation using unsupervised dimensionality reduction
Swieboda, Dominika , Beaver, Jacob T., Chakraborty, Rana , Johnson, Erica L. , Skountzou, Ioanna

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 235.19-235.19

10.4049/jimmunol.204.supp.235.19 Get It

Abstract Fetal placental macrophages (Hofbauer cells (HCs)) appear at 18 days post-conception and are maintained throughout pregnancy. Despite their identification more than a century ago, there are few studies characterizing the evolution of human HC phenotype through gestation. Using high-dimensional flow cytometry, we measured expression of CD68, CD80, CD86, HLA-DR, CD163, CD206, and CD209 on human HCs ex vivo. This panel includes markers previously validated on term human HCs for immune activation (CD80, CD86) and modulation (DC-SIGN, HLA-DR). To best capture the spectrum of HC diversity across gestation, we employed an unbiased approach to analyze processed datasets from HCs isolated from placentae 12–17 weeks gestational age (n=5), 17–24 weeks gestational age (n=7) and at term (n=5) using t-distributed stochastic neighbor embedding analysis (tSNE). HC populations were more diverse early in pregnancy and at term, compared to the second trimester; this is anticipated given the changing microenvironment following initial placental anchoring to eventual parturition. Marker expression heatmaps were generated to assess gestation-dependent changes in HC phenotype; HCs expressing activation markers were most frequent in early gestation, and reduced by term. HCs bearing markers of immune modulation were most frequent at mid-gestation, and least in early gestation. These results demonstrate the power of utilizing computational methods to analyze high-dimensional flow cytometry data collected from an understudied cell type and demonstrate how HCs phenotypically evolve during human pregnancy.
Temporal Maternal Influence on the Developing Microbiota
Greenfield, Kara Grace, Floyd, Alex, Greenfield, Kara G , Floyd, Alex, Newberry, Rodney D. , Knoop, Kathryn A.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 235.25-235.25

10.4049/jimmunol.204.supp.235.25 Get It

Abstract The microbiota present on every mucosal surface of the body is imperative for the development and maintenance of the immune system. Disruption of the microbiota from environmental factors can affect immune components in both the mucosal and the systemic immune compartments. Following birth in mammals including humans and mice, the microbiota rapidly develops and matures into a composition generally seen in adults when infants are weaned. Gut microbiota composition is directly affected by feeding type, breast-fed vs formula-feeding, in humans, and the microbiota associated with breastfeeding has been shown to promote intestinal health. As the composition of breastmilk changes throughout lactation, we hypothesize maternal provided factors within breastmilk support the development of the microbiota in a temporally sensitive manner. To address this question we asynchronously cross-fostered (ACF) litters born on day 1 to dams who had delivered 2 weeks earlier. Gut microbiota composition was assessed by 16S analysis of stool samples at the time of weaning, and while the microbiota of synchronous cross-fostered pups resembled the microbiota of their foster dam, the microbiota of ASF mice was different from both their foster dam and the healthy microbiota seen in weanling mice. ACF mice had a significant reduction in bacteroides and firmicute species, species that generally represent the majority of the bacteria within a healthy microbiota, and expansion in prevotella species, which include clinically important opportunistic pathogens, suggesting ACF mice contain a dysbiotic microbiota. Future work will explore and identify what temporally dependent components in breast milk support the development of a healthy microbiota.
ST8Sia6 overexpression in beta cells prevents onset of autoimmune diabetes in the murine NOD model
Choe, Justin, Belmonte, Paul , Rajcula, Matthew, McCue, Shaylene , Shapiro, Michael J. , Shapiro, Michael J, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 237.24-237.24

10.4049/jimmunol.204.supp.237.24 Get It

Abstract Cell surface hypersialylation is used by malignant cells as a survival mechanism, leveraging interactions with Siglec receptors to dampen the immune response. In this study, we aimed to harness this mechanism to prevent autoimmune rejection of beta cells in the context of type 1 diabetes. Mice engineered to overexpress the sialyltransferase ST8Sia6 in beta cell (BST) were generated and crossed to the non-obese diabetic (NOD) mouse for 10 generations. The blood glucose of these mice compared to non-overexpressing littermates was assessed twice weekly to determine diabetes incidence, defined as 3 consecutive blood glucose readings above 250 mg/dL. Analysis of female BST mice aged 15 weeks or greater showed no incidence of overt diabetes, while littermates developed diabetes. BST males aged 15 weeks or greater also had no disease incidence, while littermate controls also became diabetic. An insulin tolerance test demonstrated no significant difference between BST mice and littermates, though the BST had significantly higher blood glucose during a glucose challenge, possibly representing insulin hypersecretion by littermate islets in a stressed pre-diabetic state. Histologic analysis of young BST and littermate pancreata showed no differences, with similar levels of insulitis at 8 weeks. Thus, the overexpression of ST8Sia6 has been shown to mitigate autoimmune attack in the NOD model and presents a novel path forward for prevention of islet transplant rejection.